Identification, synthesis, and biological evaluation of the metabolites of 3-amino-6-(3'-aminopropyl)-5h-indeno[1,2- c]isoquinoline-5,11-(6h)dione (AM6-36), a promising rexinoid lead compound for the development of cancer chemotherapeutic and chemopreventive agents

Lian Chen, Martin Conda-Sheridan, P. V.Narasimha Reddy, Andrew Morrell, Eun Jung Park, Tamara P. Kondratyuk, John M. Pezzuto, Richard B. Van Breemen, Mark Cushman

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Activation of the retinoid X receptor (RXR), which is involved in cell proliferation, differentiation, and apoptosis, is a strategy for cancer chemotherapy and chemoprevention, and 3-amino-6-(3′-aminopropyl)-5H- indeno[1,2-c]isoquinoline-5,11-(6H)dione (AM6-36) (3) is among the few RXR ligands known. The presently reported studies of 3 include its binding to human plasma proteins, metabolic stability using human liver microsomes, metabolism by human liver microsomes and hepatocytes, and in vivo disposition in rat serum, liver, and mammary tissue. Compound 3 was 75% bound to human plasma proteins, and its metabolic stability was much greater than propranolol. One phase I metabolite was formed by human liver microsomes, seven phase I and II metabolites were formed by human hepatocytes, and five metabolites were detected in rat serum and liver after oral administration. The putative metabolites predicted using LC-MS-MS were synthesized to confirm their structures and to provide sufficient material for investigation of induction of RXRE transcriptional activity and inhibition of NFκB.

Original languageEnglish (US)
Pages (from-to)5965-5981
Number of pages17
JournalJournal of Medicinal Chemistry
Volume55
Issue number12
DOIs
StatePublished - Jun 28 2012

Fingerprint

Liver Microsomes
Retinoid X Receptors
Neoplasms
Blood Proteins
Hepatocytes
Protein Stability
Liver
Chemoprevention
Serum
Propranolol
Oral Administration
3-amino-6-(3'-aminopropyl)-5H-indeno(1,2-c)isoquinoline-5,11-(6H)dione
3-amino-6-(3-aminopropyl)-5,6-dihydro-5,11-dioxo-11H-indeno(1,2-c)isoquinoline
Cell Differentiation
Breast
Cell Proliferation
Apoptosis
Ligands
Drug Therapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Identification, synthesis, and biological evaluation of the metabolites of 3-amino-6-(3'-aminopropyl)-5h-indeno[1,2- c]isoquinoline-5,11-(6h)dione (AM6-36), a promising rexinoid lead compound for the development of cancer chemotherapeutic and chemopreventive agents. / Chen, Lian; Conda-Sheridan, Martin; Reddy, P. V.Narasimha; Morrell, Andrew; Park, Eun Jung; Kondratyuk, Tamara P.; Pezzuto, John M.; Van Breemen, Richard B.; Cushman, Mark.

In: Journal of Medicinal Chemistry, Vol. 55, No. 12, 28.06.2012, p. 5965-5981.

Research output: Contribution to journalArticle

@article{be52b44ccfb24d3c8f1fe9ef4e80ca5e,
title = "Identification, synthesis, and biological evaluation of the metabolites of 3-amino-6-(3'-aminopropyl)-5h-indeno[1,2- c]isoquinoline-5,11-(6h)dione (AM6-36), a promising rexinoid lead compound for the development of cancer chemotherapeutic and chemopreventive agents",
abstract = "Activation of the retinoid X receptor (RXR), which is involved in cell proliferation, differentiation, and apoptosis, is a strategy for cancer chemotherapy and chemoprevention, and 3-amino-6-(3′-aminopropyl)-5H- indeno[1,2-c]isoquinoline-5,11-(6H)dione (AM6-36) (3) is among the few RXR ligands known. The presently reported studies of 3 include its binding to human plasma proteins, metabolic stability using human liver microsomes, metabolism by human liver microsomes and hepatocytes, and in vivo disposition in rat serum, liver, and mammary tissue. Compound 3 was 75{\%} bound to human plasma proteins, and its metabolic stability was much greater than propranolol. One phase I metabolite was formed by human liver microsomes, seven phase I and II metabolites were formed by human hepatocytes, and five metabolites were detected in rat serum and liver after oral administration. The putative metabolites predicted using LC-MS-MS were synthesized to confirm their structures and to provide sufficient material for investigation of induction of RXRE transcriptional activity and inhibition of NFκB.",
author = "Lian Chen and Martin Conda-Sheridan and Reddy, {P. V.Narasimha} and Andrew Morrell and Park, {Eun Jung} and Kondratyuk, {Tamara P.} and Pezzuto, {John M.} and {Van Breemen}, {Richard B.} and Mark Cushman",
year = "2012",
month = "6",
day = "28",
doi = "10.1021/jm3006806",
language = "English (US)",
volume = "55",
pages = "5965--5981",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "12",

}

TY - JOUR

T1 - Identification, synthesis, and biological evaluation of the metabolites of 3-amino-6-(3'-aminopropyl)-5h-indeno[1,2- c]isoquinoline-5,11-(6h)dione (AM6-36), a promising rexinoid lead compound for the development of cancer chemotherapeutic and chemopreventive agents

AU - Chen, Lian

AU - Conda-Sheridan, Martin

AU - Reddy, P. V.Narasimha

AU - Morrell, Andrew

AU - Park, Eun Jung

AU - Kondratyuk, Tamara P.

AU - Pezzuto, John M.

AU - Van Breemen, Richard B.

AU - Cushman, Mark

PY - 2012/6/28

Y1 - 2012/6/28

N2 - Activation of the retinoid X receptor (RXR), which is involved in cell proliferation, differentiation, and apoptosis, is a strategy for cancer chemotherapy and chemoprevention, and 3-amino-6-(3′-aminopropyl)-5H- indeno[1,2-c]isoquinoline-5,11-(6H)dione (AM6-36) (3) is among the few RXR ligands known. The presently reported studies of 3 include its binding to human plasma proteins, metabolic stability using human liver microsomes, metabolism by human liver microsomes and hepatocytes, and in vivo disposition in rat serum, liver, and mammary tissue. Compound 3 was 75% bound to human plasma proteins, and its metabolic stability was much greater than propranolol. One phase I metabolite was formed by human liver microsomes, seven phase I and II metabolites were formed by human hepatocytes, and five metabolites were detected in rat serum and liver after oral administration. The putative metabolites predicted using LC-MS-MS were synthesized to confirm their structures and to provide sufficient material for investigation of induction of RXRE transcriptional activity and inhibition of NFκB.

AB - Activation of the retinoid X receptor (RXR), which is involved in cell proliferation, differentiation, and apoptosis, is a strategy for cancer chemotherapy and chemoprevention, and 3-amino-6-(3′-aminopropyl)-5H- indeno[1,2-c]isoquinoline-5,11-(6H)dione (AM6-36) (3) is among the few RXR ligands known. The presently reported studies of 3 include its binding to human plasma proteins, metabolic stability using human liver microsomes, metabolism by human liver microsomes and hepatocytes, and in vivo disposition in rat serum, liver, and mammary tissue. Compound 3 was 75% bound to human plasma proteins, and its metabolic stability was much greater than propranolol. One phase I metabolite was formed by human liver microsomes, seven phase I and II metabolites were formed by human hepatocytes, and five metabolites were detected in rat serum and liver after oral administration. The putative metabolites predicted using LC-MS-MS were synthesized to confirm their structures and to provide sufficient material for investigation of induction of RXRE transcriptional activity and inhibition of NFκB.

UR - http://www.scopus.com/inward/record.url?scp=84863113291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863113291&partnerID=8YFLogxK

U2 - 10.1021/jm3006806

DO - 10.1021/jm3006806

M3 - Article

C2 - 22712432

AN - SCOPUS:84863113291

VL - 55

SP - 5965

EP - 5981

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 12

ER -